CASP9 and gastric cancer: Western blot analysis revealed dose-dependent upregulation of cleaved caspase-9 in EGFR-high CN GC cells treated with pyrotinib (0–2 μM), with no significant changes in EGFR-low CN cells (Fig. 1F).